253 related articles for article (PubMed ID: 35091434)
1. Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8
Booty MG; Hlavaty KA; Stockmann A; Ozay EI; Smith C; Tian L; How E; Subramanya D; Venkitaraman A; Yee C; Pryor O; Volk K; Blagovic K; Vicente-Suarez I; Yarar D; Myint M; Merino A; Chow J; Abdeljawad T; An H; Liu S; Mao S; Heimann M; Talarico L; Jacques MK; Chong E; Pomerance L; Gonzalez JT; von Andrian UH; Jensen KF; Langer R; Knoetgen H; Trumpfheller C; Umaña P; Bernstein H; Sharei A; Loughhead SM
J Immunol; 2022 Feb; 208(4):929-940. PubMed ID: 35091434
[TBL] [Abstract][Full Text] [Related]
2. Type I interferon activates MHC class I-dressed CD11b
Duong E; Fessenden TB; Lutz E; Dinter T; Yim L; Blatt S; Bhutkar A; Wittrup KD; Spranger S
Immunity; 2022 Feb; 55(2):308-323.e9. PubMed ID: 34800368
[TBL] [Abstract][Full Text] [Related]
3. Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity.
Prins RM; Incardona F; Lau R; Lee P; Claus S; Zhang W; Black KL; Wheeler CJ
J Immunol; 2004 Feb; 172(3):1602-11. PubMed ID: 14734741
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation.
Wang X; Li H; Matte-Martone C; Cui W; Li N; Tan HS; Roopenian D; Shlomchik WD
Blood; 2011 Dec; 118(24):6426-37. PubMed ID: 21963602
[TBL] [Abstract][Full Text] [Related]
5. Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141
Huang J; Zhou J; Ghinnagow R; Seki T; Iketani S; Soulard D; Paczkowski P; Tsuji Y; MacKay S; Cruz LJ; Trottein F; Tsuji M
Front Immunol; 2020; 11():2043. PubMed ID: 32973811
[TBL] [Abstract][Full Text] [Related]
6. Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages.
Tobian AA; Canaday DH; Boom WH; Harding CV
J Immunol; 2004 May; 172(9):5277-86. PubMed ID: 15100266
[TBL] [Abstract][Full Text] [Related]
7. Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells.
Jiang W; Lederman MM; Harding CV; Sieg SF
J Immunol; 2011 Feb; 186(4):2080-6. PubMed ID: 21239717
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral CD8
Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
[TBL] [Abstract][Full Text] [Related]
9. Mucosally delivered dendritic cells activate T cells independently of IL-12 and endogenous APCs.
McCormick S; Santosuosso M; Small CL; Shaler CR; Zhang X; Jeyanathan M; Mu J; Takenaka S; Ngai P; Gauldie J; Wan Y; Xing Z
J Immunol; 2008 Aug; 181(4):2356-67. PubMed ID: 18684925
[TBL] [Abstract][Full Text] [Related]
10. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
Parkhurst MR; DePan C; Riley JP; Rosenberg SA; Shu S
J Immunol; 2003 May; 170(10):5317-25. PubMed ID: 12734382
[TBL] [Abstract][Full Text] [Related]
11. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
12. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
[TBL] [Abstract][Full Text] [Related]
13. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
14. Steady-state antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells.
Hirosue S; Vokali E; Raghavan VR; Rincon-Restrepo M; Lund AW; Corthésy-Henrioud P; Capotosti F; Halin Winter C; Hugues S; Swartz MA
J Immunol; 2014 Jun; 192(11):5002-11. PubMed ID: 24795456
[TBL] [Abstract][Full Text] [Related]
15. Activation of human CD8+ alpha beta TCR+ cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway.
Canaday DH; Ziebold C; Noss EH; Chervenak KA; Harding CV; Boom WH
J Immunol; 1999 Jan; 162(1):372-9. PubMed ID: 9886409
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
[TBL] [Abstract][Full Text] [Related]
17. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells can prime anti-tumor CD8
MacNabb BW; Tumuluru S; Chen X; Godfrey J; Kasal DN; Yu J; Jongsma MLM; Spaapen RM; Kline DE; Kline J
Immunity; 2022 Jun; 55(6):982-997.e8. PubMed ID: 35617964
[TBL] [Abstract][Full Text] [Related]
20. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
